Disease Detail

Profile Responses 1
Clinical Trials 328

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail
TP53 C238F	APR-246 + Cisplatin	fallopian tube cancer	sensitive	detail...

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT00565851	Phase III	Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA	2
NCT00993655	Phase III	Cisplatin Paclitaxel Carboplatin	Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Completed	USA \| GBR \| ESP \| CAN	0
NCT01031381	Phase II	Bevacizumab + Everolimus	Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer	Completed	USA	0
NCT01116648	Phase Ib/II	Olaparib Cediranib + Olaparib	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	Active, not recruiting	USA	0
NCT01132014	Phase I	Bevacizumab Dacarbazine	Autologous OC-DC Vaccine in Ovarian Cancer	Completed	USA	0
NCT01146795	Phase II	Bevacizumab + Carboplatin + Paclitaxel	Neoadjuvant Therapy for Ovarian Cancer	Completed	USA	0
NCT01264432	Phase I	Veliparib	Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	Completed	USA \| CAN	0
NCT01305213	Phase Ib/II	Fosbretabulin Bevacizumab	Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	Completed	USA	0
NCT01312376	Phase I	Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine	Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer	Terminated	USA	0
NCT01325441	Phase Ib/II	Napabucasin + Paclitaxel	A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies	Completed	USA \| CAN	0
NCT01357161	Phase II	Carboplatin Adavosertib Paclitaxel	A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)	Completed		0
NCT01445418	Phase I	Olaparib Carboplatin	AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer	Completed	USA	0
NCT01459380	Phase I	Carboplatin Doxorubicin Veliparib Bevacizumab	Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Completed	USA	0
NCT01482715	Phase Ib/II	Rucaparib	A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)	Completed	USA \| ISR \| GBR \| ESP \| CAN	0
NCT01493505	Phase III	Carboplatin Paclitaxel Trebananib	TRINOVA-3	Terminated	USA \| NLD \| ITA \| GRC \| ESP \| DNK \| DEU \| CAN \| BEL \| AUT	4
NCT01579812	Phase II	Metformin	Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients	Completed	USA	0
NCT01610206	Phase II	Gemcitabine + Pazopanib Gemcitabine	A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer	Completed	USA	0
NCT01649336	Phase I	Binimetinib + Paclitaxel	A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	Completed	USA	0
NCT01652079	Phase II	Bevacizumab + NLG207	CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer	Completed	USA	0
NCT01663857	Phase Ib/II	Ralimetinib Carboplatin + Gemcitabine	A Study of LY2228820 for Recurrent Ovarian Cancer	Completed	USA \| DEU \| BEL \| AUS	0
NCT01690468	Phase Ib/II	Carboplatin + Triciribine	PTX-200 and Carboplatin in Ovarian Cancer	Terminated	USA	0
NCT01749397	Phase I	Floxuridine + Veliparib	Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer	Completed	USA	0
NCT01844986	Phase III	Olaparib	Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| CAN \| BRA \| AUS	4
NCT01846611	Phase III	Pegylated liposomal doxorubicin Dexamethasone	A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Completed	USA \| POL \| NZL \| ISR \| GBR \| CHE \| AUS	3
NCT01847274	Phase III	Niraparib	A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer	Completed	USA \| SWE \| POL \| NOR \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUT	0
NCT01853306	Phase I	Veliparib	A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors	Completed		0
NCT01853644	Phase II	Tivozanib	Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Completed	USA	0
NCT01874353	Phase III	Olaparib	Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS	4
NCT01891344	Phase II	Rucaparib	A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)	Completed	USA \| GBR \| FRA \| ESP \| CAN \| AUS	0
NCT01940172	Phase I	Conatumumab Birinapant	Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer	Completed	USA	0
NCT01952249	Phase Ib/II	Demcizumab Paclitaxel	A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian	Terminated	USA	0
NCT01962948	Phase II	Paclitaxel Ganetespib	Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Terminated	USA	0
NCT01968213	Phase III	Rucaparib	A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Completed	USA \| NZL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	0
NCT01972516	Phase II	Tivozanib	Tivozanib As Maintenance Therapy In GYN	Terminated	USA	0
NCT01991210	Phase II	DNIB0600A Pegylated liposomal doxorubicin	A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer	Terminated	USA \| POL \| GBR \| FRA \| ESP \| CAN \| BEL	0
NCT01995188	Phase I	Bevacizumab + Carboplatin + DNIB0600A Carboplatin + DNIB0600A	A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer	Completed	USA	0
NCT02014337	Phase I	Eribulin + Mifepristone	Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors	Completed	USA	0
NCT02046421	Phase I	Mifepristone Carboplatin + Gemcitabine	Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Completed	USA	0
NCT02050009	Phase I	Carboplatin + Metformin + Paclitaxel	Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Withdrawn	USA	0
NCT02091999	Phase I	Enfortumab vedotin-ejfv	A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4	Completed	USA \| CAN	0
NCT02118285	Phase I	Aldesleukin Epacadostat Cyclophosphamide Fludarabine	Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	Completed	USA	0
NCT02124421	Phase II	Carboplatin + Paclitaxel Cisplatin + Paclitaxel	Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer	Active, not recruiting	USA	0
NCT02199171	Phase I	Carboplatin	Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer	Completed	USA	0
NCT02203513	Phase II	Prexasertib	A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer	Terminated	USA	0
NCT02264678	Phase Ib/II	Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib	Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents	Recruiting	USA \| HUN \| GBR \| FRA \| ESP \| CAN \| BEL \| AUS	1
NCT02269293	Phase I	Carboplatin + Paclitaxel + Selinexor	Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers	Completed	USA	0
NCT02272790	Phase II	Adavosertib + Pegylated liposomal doxorubicin Adavosertib + Carboplatin Adavosertib + Gemcitabine Adavosertib + Paclitaxel	Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	USA \| NLD \| CAN	0
NCT02278783	Phase II	Regorafenib	Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer	Terminated	USA	0
NCT02282020	Phase III	Topotecan Paclitaxel Pegylated liposomal doxorubicin Gemcitabine Olaparib	Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)	Completed	USA \| POL \| ITA \| ISR \| HUN \| ESP \| CZE \| CAN \| BRA \| BEL \| ARG	2
NCT02289950	Phase II	Farletuzumab	A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer	Completed	USA \| ITA \| GBR \| ESP \| DEU \| BEL	1
NCT02312245	Phase II	Topotecan Doxorubicin Paclitaxel Gemcitabine	Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Completed	USA	0
NCT02346747	Phase II	FANG vaccine	Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL)	Active, not recruiting	USA	0
NCT02354131	Phase Ib/II	Niraparib Bevacizumab + Niraparib	Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA)	Completed	USA \| DNK	0
NCT02364713	Phase II	Pegylated liposomal doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	Active, not recruiting	USA	0
NCT02392676	Phase III	Olaparib	Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations	Withdrawn	USA \| GBR	3
NCT02432690	Phase II	Amcasertib	A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation	Terminated	USA	0
NCT02433626	Phase I	COTI-2 Cisplatin + COTI-2	Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)	Unknown status	USA	0
NCT02437812	Phase II	Paclitaxel Carboplatin Metformin	Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma	Unknown status	USA	0
NCT02446600	Phase III	Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	USA \| CAN	2
NCT02452775	Phase I	OC-L	Autologous OC-L Vaccine and Ovarian Cancer	Terminated	USA	0
NCT02476968	FDA approved	Olaparib	To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)	Completed	POL \| ITA \| HUN \| GBR \| ESP \| CZE \| CAN \| BGR	0
NCT02489006	Phase II	Olaparib	A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	Active, not recruiting	NZL \| GBR \| ESP \| CAN	0
NCT02498600	Phase II	Ipilimumab Nivolumab	Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA	0
NCT02502266	Phase II	Topotecan Paclitaxel Doxorubicin Olaparib Cediranib	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	USA \| CAN	3
NCT02534922	Phase I	Prolanta	Study of Prolanta in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC)	Unknown status	USA	0
NCT02558348	Phase Ib/II	Anlotinib	Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)	Terminated	USA	0
NCT02575807	Phase Ib/II	Epacadostat CRS-207	Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer	Terminated	USA \| CAN	0
NCT02580058	Phase III	Doxorubicin Avelumab	A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer	Completed	USA \| POL \| NOR \| NLD \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS	6
NCT02584478	Phase Ib/II	Anlotinib + Carboplatin + Paclitaxel	Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	Active, not recruiting	USA \| ITA \| GBR \| ESP	2
NCT02595892	Phase II	Berzosertib Gemcitabine	Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA	0
NCT02606305	Phase I	Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine	Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer	Completed	USA \| ESP \| CAN \| BEL	0
NCT02627430	Phase I	Onalespib + Talazoparib	Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer	Withdrawn		0
NCT02627443	Phase II	Carboplatin + Gemcitabine Berzosertib	Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA	0
NCT02631876	Phase II	Paclitaxel + Pegylated liposomal doxorubicin Gemcitabine Topotecan Mirvetuximab Soravtansine	PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer	Completed	USA \| ITA \| IRL \| GBR \| FRA \| ESP \| CZE \| CHE \| CAN \| BEL	3
NCT02649673	Phase Ib/II	LCL161 + Topotecan	LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies	Terminated	USA	0
NCT02655016	Phase III	Niraparib	A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Active, not recruiting	USA \| SWE \| POL \| NOR \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BEL	2
NCT02657889	Phase Ib/II	Niraparib + Pembrolizumab	Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)	Completed	USA	0
NCT02658214	Phase I	Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab	Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors	Completed		2
NCT02660034	Phase I	Pamiparib + Tislelizumab	The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors	Completed	USA \| NZL \| GBR \| FRA \| ESP \| AUS	0
NCT02674061	Phase II	Pembrolizumab	Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)	Completed		0
NCT02713386	Phase Ib/II	Ruxolitinib Carboplatin + Paclitaxel	Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	USA	0
NCT02718417	Phase III	Avelumab Carboplatin + Paclitaxel	Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)	Terminated	USA \| TUR \| SVK \| ROU \| POL \| NLD \| LVA \| ITA \| IRL \| HUN \| HRV \| GBR \| EST \| DEU \| CHE \| CAN \| BGR	8
NCT02725489	Phase II	Durvalumab + FANG vaccine	Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers	Completed	USA	0
NCT02726997	Phase Ib/II	Carboplatin + Durvalumab + Paclitaxel	Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer	Active, not recruiting	USA	0
NCT02728830	Phase I	Pembrolizumab	A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers	Completed	USA	0
NCT02737787	Phase I	Nivolumab + WT1 vaccine Nivolumab + NY-ESO-1 peptide vaccine	A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer	Completed	USA	0
NCT02762981	Phase Ib/II	Nab-paclitaxel + Relacorilant	Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors	Completed	USA	0
NCT02766582	Phase II	Carboplatin + Paclitaxel + Pembrolizumab	Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer	Completed	USA	0
NCT02785250	Phase I	Cyclophosphamide + Epacadostat + Maveropepimut-S	Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer	Active, not recruiting	USA \| CAN	0
NCT02788708	Phase I	Lenvatinib + Paclitaxel	Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer	Completed	USA	0
NCT02824042	Phase I	Anetumab ravtansine + Itraconazole Anetumab ravtansine	Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole	Completed	USA \| NLD \| FRA \| ESP \| BEL \| AUS	0
NCT02853318	Phase II	Bevacizumab + Cyclophosphamide + Pembrolizumab	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	USA	0
NCT02855944	Phase III	Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel	ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients	Completed	USA \| POL \| ITA \| ISR \| HUN \| GBR \| ESP \| CZE \| CAN \| BRA	2
NCT02865811	Phase II	Pegylated liposomal doxorubicin + Pembrolizumab	Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer	Completed	USA	0
NCT02873962	Phase II	Bevacizumab + Nivolumab	A Phase II Study Of Nivolumab/ Bevacizumab	Active, not recruiting	USA	0
NCT02884648	Phase II	Bevacizumab	Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery	Recruiting	USA	0
NCT02900560	Phase II	Azacitidine + Pembrolizumab	Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer	Terminated	USA	0
NCT02901899	Phase II	Guadecitabine + Pembrolizumab	Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Completed	USA	0
NCT02915523	Phase Ib/II	Avelumab Avelumab + Entinostat	Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer	Completed	USA	0
NCT02923739	Phase II	Bevacizumab + Emactuzumab + Paclitaxel Bevacizumab + Paclitaxel	Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT	Terminated	USA	0
NCT02943317	Phase I	Defactinib Avelumab	Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer	Terminated	USA	0
NCT02948101	Phase II	Cyclophosphamide + PD 0360324	Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer	Withdrawn	USA	0
NCT02948426	Phase I	Interferon gamma + Peginterferon alfa-2b	Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer	Terminated	USA	0
NCT02963831	Phase Ib/II	Durvalumab + ONCOS-102	A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies	Completed	USA	0
NCT02996825	Phase I	Gemcitabine + Mirvetuximab Soravtansine	Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	Completed	USA	0
NCT03026062	Phase II	Tremelimumab Durvalumab + Tremelimumab Durvalumab	Durvalumab and Tremelimumab in Combo Versus Sequential	Active, not recruiting	USA	0
NCT03029598	Phase Ib/II	Carboplatin + Pembrolizumab	Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	USA	0
NCT03030287	Phase I	Navicixizumab + Paclitaxel	A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer	Completed	USA	0
NCT03038100	Phase III	Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)	Completed	USA \| TUR \| SWE \| POL \| NOR \| ITA \| ISR \| GRC \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| BRA \| BEL \| AUT \| AUS	4
NCT03056833	Phase I	Carboplatin + Paclitaxel + Ribociclib	Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer	Completed	USA	0
NCT03079687	Expanded access	Olaparib	Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.	Approved for marketing	USA	0
NCT03093155	Phase II	Bevacizumab + Ixabepilone Ixabepilone	Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab	Completed	USA	0
NCT03106987	Phase III	Olaparib	A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO)	Completed	POL \| NOR \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL	0
NCT03113487	Phase II	MVAp53 + Pembrolizumab	P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA	0
NCT03126812	Phase Ib/II	Carboplatin + Paclitaxel + Pembrolizumab	Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer	Completed	NLD	0
NCT03134638	Phase I	Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365	A Study of SY-1365 in Adult Patients With Advanced Solid Tumors	Terminated	USA \| FRA \| CAN	0
NCT03138408	Phase I	SC-004 Budigalimab + SC-004	SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers	Terminated	USA	0
NCT03206177	Phase I	Carboplatin + Galunisertib + Paclitaxel	Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary	Completed	USA	0
NCT03213964	Phase I	Aldesleukin + FATE-NK100	Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int	Completed	USA	0
NCT03245892	Phase I	Carboplatin + Nivolumab + Paclitaxel	A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer	Active, not recruiting	USA	0
NCT03283943	Phase I	Durvalumab	PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.	Unknown status	CAN	0
NCT03287271	Phase Ib/II	Defactinib	ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK	Recruiting	USA	0
NCT03294694	Phase I	Fulvestrant + Ribociclib + Spartalizumab Ribociclib + Spartalizumab	Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer	Terminated	USA	0
NCT03312114	Phase II	Avelumab	Anti—PD-L1 and SAbR for Ovarian Cancer	Terminated	USA	0
NCT03319628	Phase I	XMT-1536	First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b	Active, not recruiting	USA	0
NCT03326193	Phase II	Bevacizumab + Niraparib	Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Completed	USA	0
NCT03329950	Phase I	CDX-1140 + CDX-301 CDX-1140	A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors	Completed	USA	0
NCT03353831	Phase III	Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Bevacizumab + Paclitaxel	Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer	Active, not recruiting	SWE \| NOR \| LTU \| FRA \| FIN \| EST \| ESP \| DNK \| DEU \| CHE \| BEL \| AUT	0
NCT03363867	Phase II	Atezolizumab + Bevacizumab + Cobimetinib	BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)	Active, not recruiting	AUS	0
NCT03402841	Phase III	Olaparib	Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)	Completed	SWE \| SVN \| ROU \| POL \| NOR \| NLD \| ITA \| ISR \| GBR \| FIN \| ESP \| DNK \| CZE \| CHE \| CAN \| BGR \| BEL \| AUT	1
NCT03410784	Phase II	Carboplatin + Paclitaxel + Pembrolizumab	Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (MITO28MaNGOov4)	Recruiting	ITA	0
NCT03414047	Phase II	Prexasertib	A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer	Completed	USA \| ITA \| ISR \| GBR \| ESP \| BEL \| AUS	1
NCT03430700	Phase II	Pembrolizumab	Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT)	Active, not recruiting	GBR	0
NCT03462212	Phase Ib/II	Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel	Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25)	Recruiting	ITA	0
NCT03462342	Phase II	Ceralasertib + Olaparib	Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)	Active, not recruiting	USA	0
NCT03508570	Phase I	Nivolumab Ipilimumab + Nivolumab	Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	Active, not recruiting	USA	0
NCT03519178	Phase II	PF-06873600	A Study of PF-06873600 in People With Cancer	Active, not recruiting	USA \| CAN \| BGR	3
NCT03522246	Phase III	Rucaparib Nivolumab Nivolumab + Rucaparib	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)	Active, not recruiting	USA \| TUR \| SWE \| ROU \| POL \| NZL \| ITA \| ISR \| IRL \| GRC \| GBR \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUS	5
NCT03539328	Phase II	Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab	Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer (MITO27)	Unknown status	ITA	0
NCT03552471	Phase I	Mirvetuximab Soravtansine + Rucaparib	Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	USA	0
NCT03558139	Phase I	Avelumab + Hu5F9-G4	A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer	Completed	USA	0
NCT03564340	Phase Ib/II	Cemiplimab + REGN4018 REGN4018	Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer	Recruiting	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| BEL \| AUS	1
NCT03574779	Phase II	Bevacizumab + Dostarlimab-gxly + Niraparib	Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL)	Active, not recruiting	USA \| TUR \| ESP \| CAN	0
NCT03579316	Phase II	Olaparib Adavosertib + Olaparib	Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA	0
NCT03585764	Phase I	MOv19-BBz CAR T cells	MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Terminated	USA	0
NCT03586661	Phase I	Copanlisib + Niraparib	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA	0
NCT03587311	Phase II	Anetumab ravtansine + Bevacizumab Bevacizumab + Paclitaxel	Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	USA \| CAN	0
NCT03607955	Phase I	AVB-S6-500 + Carboplatin + Paclitaxel	Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy	Withdrawn		0
NCT03639246	Phase Ib/II	AVB-S6-500 + Paclitaxel AVB-S6-500 + Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin	Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer	Completed	USA	0
NCT03642132	Phase III	Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Talazoparib Avelumab + Carboplatin + Paclitaxel + Talazoparib	Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)	Terminated	USA \| ITA \| IRL \| BEL \| AUS	5
NCT03657043	Phase II	Tisotumab vedotin-tftv	A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)	Completed	USA \| ITA \| IRL \| ESP \| DNK \| BEL	0
NCT03695380	Phase I	Atezolizumab + Cobimetinib + Niraparib Cobimetinib + Niraparib	A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer	Completed	USA \| ITA \| ESP	0
NCT03704467	Phase II	Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Avelumab + Berzosertib + Carboplatin	Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer	Completed	USA \| GBR \| BEL	0
NCT03732950	Phase II	Pembrolizumab	Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer	Active, not recruiting	USA	0
NCT03737643	Phase III	Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)	Active, not recruiting	USA \| TUR \| ROU \| POL \| ITA \| HUN \| FRA \| FIN \| ESP \| DNK \| DEU \| CAN \| BRA \| BGR \| BEL \| AUT	4
NCT03740165	Phase III	Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab	Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)	Active, not recruiting	USA \| TUR \| POL \| ITA \| ISR \| HUN \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS	8
NCT03748186	Phase I	Luveltamab Tazevibulin	Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers	Completed	USA \| ESP	0
NCT03761914	Phase Ib/II	Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim	Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers	Active, not recruiting	USA	0
NCT03824704	Phase II	Nivolumab + Rucaparib	A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)	Terminated	USA	0
NCT03836352	Phase II	Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab	Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors	Active, not recruiting	USA \| CAN	0
NCT03840200	Phase Ib/II	Ipatasertib + Rucaparib	A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.	Completed	USA \| ITA \| ESP \| AUS	1
NCT03861403	Phase Ib/II	Avelumab + Cyclophosphamide + TRX518	A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors	Terminated	USA	0
NCT03872206	Phase Ib/II	HPN536	Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression	Completed	USA	0
NCT03891576	Phase II	Niraparib	Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton)	Active, not recruiting	ITA \| DEU	0
NCT03907527	Phase I	PRGN-3005	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	USA	0
NCT03934814	Phase I	Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab	Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma	Completed	USA	1
NCT03943173	Phase I	Olaparib	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	Active, not recruiting	USA	0
NCT03955471	Phase II	Dostarlimab-gxly + Niraparib	Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)	Terminated	USA	0
NCT03968406	Phase I	Talazoparib	Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	Recruiting	USA	0
NCT04019288	Phase Ib/II	AVB-S6-500 + Durvalumab	AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	USA	0
NCT04024878	Phase I	NeoVax + Nivolumab	NeoVax With Nivolumab in Patients With Ovarian Cancer	Active, not recruiting	USA	0
NCT04034927	Phase II	Olaparib Olaparib + Tremelimumab	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	Active, not recruiting	USA	0
NCT04055649	Phase II	ONC201 + Paclitaxel	ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	USA	0
NCT04091204	Phase II	Olaparib	Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study (MITO 31)	Recruiting	ITA	0
NCT04092270	Phase I	Pegylated liposomal doxorubicin + Peposertib	A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients	Suspended	USA	0
NCT04095273	Phase I	Elimusertib + Pembrolizumab	Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug	Completed	USA \| GBR \| ESP \| DEU \| CHE	0
NCT04105335	Phase I	CEBPA-51 + Pembrolizumab	A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT)	Active, not recruiting	GBR	0
NCT04111978	Phase III	Letrozole	MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (MATAO)	Recruiting	DEU \| CHE \| AUT	0
NCT04149145	Phase I	Niraparib + VX-803	Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer	Withdrawn		0
NCT04196257	Phase I	BP1001-A BP1001-A + Paclitaxel	BP1001-A in Patients With Advanced or Recurrent Solid Tumors	Unknown status	USA	0
NCT04209855	Phase III	Paclitaxel Pegylated liposomal doxorubicin Mirvetuximab Soravtansine Topotecan	A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRalpha) Expression (MIRASOL)	Completed	USA \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BGR \| BEL \| AUS	7
NCT04227522	Phase III	Rucaparib	Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (MAMOC)	Active, not recruiting	DEU	0
NCT04239014	Phase II	Olaparib Ceralasertib + Olaparib	A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE)	Withdrawn	USA \| ITA \| ESP \| CAN	0
NCT04261465	Phase II	Carboplatin + Olaparib + Paclitaxel	NUVOLA TRIAL Open-label Multicentre Study (NUVOLA)	Unknown status	ITA	0
NCT04267939	Phase I	Elimusertib + Niraparib	ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer	Terminated	USA	0
NCT04274426	Phase II	Carboplatin + Paclitaxel Carboplatin + Gemcitabine Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Mirvetuximab Soravtansine	Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA)	Active, not recruiting	DEU	0
NCT04293094	Phase I	AMG 650	Study of AMG 650 in Adult Participants With Advanced Solid Tumors	Completed	USA \| ITA \| ESP \| CAN \| BEL \| AUS	1
NCT04296890	Phase III	Mirvetuximab Soravtansine	A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression	Completed	USA \| POL \| ITA \| ISR \| IRL \| ESP \| DEU \| CZE \| BGR \| BEL \| AUS	0
NCT04300556	Phase Ib/II	MORAb-202	A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types	Recruiting	USA \| GBR \| FRA \| ESP	0
NCT04374630	Phase II	Afuresertib + Paclitaxel Paclitaxel	Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)	Completed	USA	1
NCT04375956	Phase II	Pembrolizumab	Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (MITO 27)	Recruiting	ITA	0
NCT04377087	Phase II	Olaparib	Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer	Terminated	USA	0
NCT04387227	Phase II	Carboplatin + Pembrolizumab	Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	USA	0
NCT04406623	Phase I	SL-172154	Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer	Completed	USA	0
NCT04460807	Phase III	Exemestane	Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT)	Terminated	ITA	0
NCT04469764	Phase II	Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib	Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer	Recruiting	USA	0
NCT04493619	Phase Ib/II	Carboplatin + PLX2853 PLX2853	PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer	Terminated	USA \| CAN	0
NCT04498520	Phase I	Abexinostat + Fulvestrant + Palbociclib	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	Withdrawn		0
NCT04510584	Phase II	Atezolizumab + Bevacizumab	Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer	Withdrawn	CAN	0
NCT04516447	Phase I	Pegylated liposomal doxorubicin + ZN-c3 Carboplatin + ZN-c3	A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer	Recruiting	USA \| BGR \| AUS	4
NCT04553133	Phase II	PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091	PF-07104091 as a Single Agent and in Combination Therapy	Active, not recruiting	USA \| BGR \| ARG	3
NCT04561362	Phase Ib/II	BT8009 BT8009 + Pembrolizumab	Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| CAN	0
NCT04561817	Phase II	Ipatasertib + Paclitaxel	To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer	Withdrawn	USA	0
NCT04575961	Phase II	Carboplatin + Pegylated liposomal doxorubicin + Pembrolizumab Carboplatin + Gemcitabine + Pembrolizumab	Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION)	Recruiting	DEU	0
NCT04586335	Phase I	CYH33 + Olaparib	Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Terminated	USA \| AUS	1
NCT04590326	Phase Ib/II	REGN4018 + REGN5668 Cemiplimab + REGN5668	Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer.	Recruiting	USA \| BEL	0
NCT04592653	Phase Ib/II	ALKS 4230 ALKS 4230 + Pembrolizumab	Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3)	Active, not recruiting	USA \| ESP	0
NCT04598321	Phase I	Talazoparib	BrUOG 390: Neoadjuvant Treatment With Talazoparib	Terminated	USA	0
NCT04616534	Phase I	Elimusertib + Gemcitabine	Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	Active, not recruiting	USA	0
NCT04630769	Phase I	Aldesleukin + FT516 Aldesleukin + FT516 + MGA271	FT516 and IL2 With Enoblituzumab for Ovarian Cancer	Completed	USA	0
NCT04669002	Phase II	NLG207 + Olaparib	EP0057 in Combination With Olaparib in Advanced Ovarian Cancer	Completed	USA \| HUN \| GBR	0
NCT04670068	Phase I	CAR.B7-H3T cells Cyclophosphamide + Fludarabine	Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian	Recruiting	USA	0
NCT04673448	Phase I	Dostarlimab-gxly + Niraparib	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	USA	0
NCT04676334	Phase III	Rucaparib	CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)	Completed	POL \| ITA \| ISR \| GBR \| CAN	1
NCT04679064	Phase III	Bevacizumab + Gemcitabine Dostarlimab-gxly + Niraparib Pegylated liposomal doxorubicin Bevacizumab + Topotecan Paclitaxel Topotecan Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine	Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33)	Recruiting	ITA	0
NCT04711161	Phase I	GRN-300 GRN-300 + Paclitaxel	First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.	Suspended	USA	0
NCT04726332	Phase I	Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102	Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)	Terminated	USA	0
NCT04729387	Phase III	Pegylated liposomal doxorubicin Paclitaxel Alpelisib + Olaparib	Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected	Active, not recruiting	USA \| TUR \| SVK \| NLD \| ITA \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT04739800	Phase II	Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Cediranib + Durvalumab Cediranib + Olaparib Cediranib + Durvalumab + Olaparib	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	Active, not recruiting	USA	1
NCT04742075	Phase II	Olaparib Durvalumab + Olaparib Durvalumab + Olaparib + UV1 Telomerase peptide vaccine	Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (DOVACC)	Recruiting	DNK	0
NCT04752826	Phase Ib/II	BI-1808 + Pembrolizumab BI-1808	BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20)	Recruiting	USA \| SWE \| HUN \| GBR \| DNK	1
NCT04753216	Phase II	Bevacizumab + Liposomal irinotecan	Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	USA	0
NCT04781088	Phase II	Lenvatinib + Paclitaxel + Pembrolizumab	Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	USA	0
NCT04809805	Phase I	BAY2666605	A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer	Terminated	USA	0
NCT04814875	Phase Ib/II	ATX101 + Carboplatin + Pegylated liposomal doxorubicin	A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy	Terminated	AUS	0
NCT04826198	Phase Ib/II	AsiDNA + Niraparib	Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib (REVOCAN)	Recruiting	FRA	0
NCT04884360	Phase III	Olaparib	D9319C00001- 1L OC Mono Global RCT (MONO-OLA1)	Active, not recruiting	TUR	9
NCT04887961	Phase II	Pegylated liposomal doxorubicin + Trabectedin	Reprab Study: PLD + Trabectedin Rechallenge (MITO36)	Unknown status	ITA	0
NCT04890613	Phase I	CX-5461	Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Recruiting	USA \| CAN	0
NCT04907968	Phase Ib/II	Carboplatin + XMT-1536	Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer (UPGRADE)	Terminated	USA	0
NCT04919629	Phase II	Bevacizumab Bevacizumab + Pegcetacoplan + Pembrolizumab Pegcetacoplan + Pembrolizumab	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	Recruiting	USA	0
NCT04925284	Phase I	XB002 Nivolumab + XB002	Study of XB002 in Subjects With Solid Tumors (JEWEL-101)	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| BEL \| AUS	1
NCT04931342	Phase II	Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab	A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors	Active, not recruiting	USA \| TUR \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| AUS	2
NCT04972981	Phase I	ADCT-901	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors	Active, not recruiting	USA \| GBR \| ESP	0
NCT04991740	Phase I	JNJ-78306358	A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors	Completed	ISR \| ESP	0
NCT05001347	Phase II	Uliledlimab	A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors	Completed	USA	0
NCT05009082	Phase III	Carboplatin + Niraparib + Paclitaxel Bevacizumab + Niraparib Bevacizumab + Carboplatin + Paclitaxel	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	Recruiting	DEU	0
NCT05041257	Phase II	Mirvetuximab Soravtansine	Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)	Active, not recruiting	USA \| ITA \| IRL \| FRA \| ESP \| CAN \| BEL \| AUS	0
NCT05065021	Phase II	Bevacizumab + Dostarlimab-gxly + Niraparib Bevacizumab + Niraparib Bevacizumab + Dostarlimab-gxly + Paclitaxel	Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	Recruiting	CAN	0
NCT05071937	Phase II	Talazoparib + ZEN-3694	ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer	Recruiting	USA	0
NCT05086692	Phase Ib/II	MDNA11 + Pembrolizumab	A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)	Recruiting	USA \| CAN \| AUS	1
NCT05092360	Phase III	Pembrolizumab ALKS 4230 Topotecan Paclitaxel Pegylated liposomal doxorubicin Gemcitabine ALKS 4230 + Pembrolizumab	Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUT \| AUS	3
NCT05092373	Phase I	Cabozantinib Atezolizumab + Nab-paclitaxel	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	Recruiting	USA	0
NCT05145569	Phase I	Bintrafusp alfa + Carboplatin + Paclitaxel Carboplatin + Paclitaxel	Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer	Withdrawn	USA	0
NCT05183984	Phase II	Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib	Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1)	Recruiting	ITA \| FRA \| ESP	3
NCT05194072	Phase I	SGN-B7H4V	A Study of SGN-B7H4V in Advanced Solid Tumors	Recruiting	USA \| ITA \| GBR \| ESP \| DEU \| CAN	0
NCT05198804	Phase Ib/II	Niraparib + ZN-c3	A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer	Active, not recruiting	USA \| FRA	0
NCT05199272	Phase Ib/II	23ME-00610	A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies	Active, not recruiting	USA \| CAN	0
NCT05200364	Phase I	Bevacizumab + Luveltamab Tazevibulin	A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer	Recruiting	USA	0
NCT05231122	Phase II	Bevacizumab + CDX-1140 + Pembrolizumab Bevacizumab + Pembrolizumab	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Recruiting	USA	0
NCT05233982	Phase II	Olaparib	MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (MITO 35a)	Recruiting	ITA	0
NCT05252390	Phase Ib/II	NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868	NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Recruiting	USA \| AUS	0
NCT05255471	Phase III	Carboplatin + Paclitaxel Olaparib Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Gemcitabine	MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B)	Recruiting	ITA	0
NCT05262530	Phase Ib/II	BNT142	Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors	Recruiting	USA \| GBR \| ESP	1
NCT05271318	Phase I	Pembrolizumab + TILT-123	Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)	Recruiting	USA \| FIN	0
NCT05276973	Phase I	Carboplatin + Ipatasertib + Paclitaxel	Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer	Recruiting	USA	0
NCT05281471	Phase III	Bevacizumab + Carboplatin Bevacizumab + Cisplatin Bevacizumab + Carboplatin + GL-ONC1 Bevacizumab + Cisplatin + GL-ONC1	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime)	Recruiting	USA	0
NCT05295589	Phase II	Topotecan Pegylated liposomal doxorubicin Copanlisib + Olaparib Paclitaxel	Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy	Withdrawn	USA	0
NCT05329532	Phase Ib/II	Modi-1 Modi-1 + Pembrolizumab	Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY)	Recruiting	GBR	0
NCT05335993	Phase II	Niraparib + Oregovomab	A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.	Active, not recruiting	USA	0
NCT05368506	Phase I	ZN-c3	ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer	Withdrawn		0
NCT05417594	Phase Ib/II	AZD9574 AZD9574 + Temozolomide	Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)	Recruiting	USA \| SWE \| GBR \| ESP \| DEU \| AUS	1
NCT05445778	Phase III	Bevacizumab + Mirvetuximab Soravtansine Bevacizumab	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)	Recruiting	USA \| TUR \| SWE \| POL \| NOR \| ITA \| ISR \| IRL \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG	3
NCT05446298	Phase II	ONC-392 + Pembrolizumab	ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)	Active, not recruiting	USA	0
NCT05446870	Phase II	Bevacizumab + Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Paclitaxel + Pembrolizumab Docetaxel + MK-4830 + Paclitaxel + Pembrolizumab Carboplatin + MK-4830 + Paclitaxel + Pembrolizumab	Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)	Completed	USA \| POL \| ITA \| ISR \| ESP \| CAN \| BEL	4
NCT05453825	Phase II	Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel	A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors	Recruiting	USA	0
NCT05456685	Phase II	Carboplatin + Mirvetuximab Soravtansine	Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRalpha) Expressing, Platinum-sensitive Epithelial Ovarian Cancer	Active, not recruiting	USA \| GBR \| ESP \| CAN \| BEL	1
NCT05483933	Phase I	Pegylated liposomal doxorubicin + SL-172154 Mirvetuximab Soravtansine + SL-172154	Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers	Active, not recruiting	USA \| GBR \| ESP \| CAN	0
NCT05500508	Phase Ib/II	AMXT1501 + Eflornithine	Oral AMXT 1501 Dicaprate in Combination With IV DFMO	Active, not recruiting	USA \| AUS	0
NCT05527184	Phase I	IMGN151	First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	Recruiting	USA	0
NCT05538091	Phase II	Atezolizumab + Vismodegib	Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	Recruiting	USA	0
NCT05548296	Phase Ib/II	Prexasertib Gemcitabine + Prexasertib	A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma	Recruiting	USA	0
NCT05568680	Phase I	SynKIR-110	SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma	Recruiting	USA	0
NCT05579366	Phase Ib/II	PRO1184	PRO1184 for Advanced Solid Tumors (PRO1184-001)	Recruiting	USA	1
NCT05613088	Phase II	Paclitaxel + Pegylated liposomal doxorubicin + Topotecan MORAb-202	A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Recruiting	USA \| ITA \| ISR \| ESP \| BEL \| AUS	3
NCT05617755	Phase I	AB-1015	AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer	Active, not recruiting	USA	0
NCT05636111	Phase I	Bevacizumab + Lurbinectedin + Paclitaxel	Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer	Recruiting	USA	0
NCT05672095	Phase Ib/II	Niraparib	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	Not yet recruiting	USA	0
NCT05691504	Phase I	APG-1252 + Cobimetinib	Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	Recruiting	USA	0
NCT05700669	Phase Ib/II	AsiDNA + Olaparib	Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors	Completed	USA	0
NCT05708924	Phase I	FT538 FT538 + MGA271	MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	Suspended	USA	0
NCT05715216	Phase II	Etigilimab + Nivolumab	EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer	Recruiting	USA	0
NCT05735080	Phase Ib/II	INX-315	Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01)	Recruiting	USA \| AUS	0
NCT05739981	Phase II	Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + GEN-1 + Paclitaxel	A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD)	Recruiting	USA	0
NCT05756907	Phase Ib/II	Atezolizumab + SON-1010 SON-1010	Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer	Recruiting	USA \| AUS	0
NCT05794659	Phase II	Carboplatin + Paclitaxel + Sargramostim Carboplatin + Paclitaxel + pUMVC3-hIGFBP-2 vaccine + Sargramostim	Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone4)	Not yet recruiting	USA	0
NCT05836324	Phase I	INCA33890	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| CHE	0
NCT05841563	Phase I	PM54	Clinical Trial of PM54 in Advanced Solid Tumors Patients.	Recruiting	USA \| ESP \| BEL	0
NCT05870748	Phase II	Luveltamab Tazevibulin Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Luveltamab Tazevibulin + Pegfilgrastim	REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1	Recruiting	USA \| NZL \| ISR \| CAN \| AUS	2
NCT05872204	Phase II	Abemaciclib + Letrozole	Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO)	Recruiting	NLD \| FRA \| BEL	0
NCT05887609	Phase II	Mirvetuximab Soravtansine + Olaparib	An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib	Recruiting	USA	0
NCT05920798	Phase Ib/II	FR alpha peptide vaccine + Pembrolizumab	A Study of FRaDCs for Ovarian Cancer	Recruiting	USA	0
NCT05922930	Phase Ib/II	TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine	Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer	Recruiting	USA	0
NCT05942300	Phase I	Carboplatin + Tulmimetostat	CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer	Recruiting	USA	0
NCT05961124	Phase II	Niraparib	Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer	Recruiting	CAN	0
NCT05983276	Phase II	Carboplatin + Decitabine + Paclitaxel + Selinexor Carboplatin + Decitabine + Paclitaxel	Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer	Recruiting	USA	0
NCT05990192	Phase II	Niraparib	SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO)	Recruiting	GBR	0
NCT06003231	Phase II	Disitamab vedotin	A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2	Recruiting	USA \| ITA \| GBR \| ESP \| CAN \| AUS	1
NCT06040970	Phase Ib/II	Cisplatin + Sacituzumab govitecan-hziy	Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer	Recruiting	USA	0
NCT06056323	Phase Ib/II	HB0045	A Study of HB0045 Injection in Patients With Advanced Solid Tumors	Recruiting	USA	0
NCT06065462	Phase Ib/II	Dostarlimab-gxly + LB-100	Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100	Recruiting	USA	0
NCT06072781	Phase III	Paclitaxel Pegylated liposomal doxorubicin Defactinib + RO5126766 Topotecan Anastrozole Letrozole	A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| CAN \| AUS	0
NCT06084416	Phase I	AMG 650	A Study of Sovilnesib in Subjects With Ovarian Cancer	Recruiting	USA	0
NCT06121401	FDA approved	Bevacizumab + Olaparib	First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients (IOLANTHE)	Recruiting	ITA	0
NCT06136884	Phase I	AO-252	A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors	Recruiting	USA	0
NCT06161025	Phase II	Paclitaxel Pegylated liposomal doxorubicin Raludotatug deruxtecan Topotecan Gemcitabine	A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| AUS	5
NCT06171789	Phase Ib/II	PRO1107	PRO1107 in Patients With Advanced Solid Tumors	Recruiting	USA	0
NCT06172478	Phase II	Patritumab deruxtecan	A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	Recruiting	USA	2
NCT06238479	Phase I	LY4101174	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Recruiting	USA \| ESP \| BEL \| AUS	1
NCT06253130	Phase Ib/II	IMP1734	A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors	Recruiting	USA \| AUS	2
NCT06255665	Phase I	JNJ-79032421	A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors	Recruiting	ESP	0
NCT06257264	Phase I	BG-68501 + Fulvestrant BG-68501	A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors	Recruiting	USA \| AUS	1
NCT06276491	Phase I	XmAb541	Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors	Recruiting	USA	0
NCT06334432	Phase Ib/II	NUV-1511	Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors	Recruiting	USA	0
NCT06342986		FT536 Cyclophosphamide + Fludarabine	Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	Recruiting	USA	0
NCT06365853	Phase II	Mirvetuximab Soravtansine	A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression	Recruiting	USA \| ITA \| IRL \| FRA \| ESP \| CAN \| BEL \| AUS	0
NCT06377267	Phase II	Bevacizumab Bevacizumab + Olaparib	Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE)	Recruiting	ESP	0
NCT06400472	Phase I	LY4170156	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	Recruiting	USA \| FRA \| ESP \| AUS	2
NCT06412120	FDA approved	Niraparib	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib	Not yet recruiting	USA	0
NCT06433219	Phase II	M1774 + Niraparib M1774 + M4076	Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)	Recruiting	USA	0
NCT06457997	Phase I	PHN-010	A Study of PHN-010 in Patients With Advanced Solid Tumors	Recruiting	USA	0
NCT06466187	Phase I	SGN-MesoC2	A Study of SGN-MesoC2 in Advanced Solid Tumors	Recruiting	USA	0
NCT06469281	Phase I	27T51 27T51 + Bevacizumab + Cemiplimab 27T51 + Cemiplimab	A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers	Recruiting	USA	0
NCT06526819	Phase Ib/II	SMP-3124	A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors	Recruiting	USA	1
NCT06547840	Phase I	MOv18IgE	A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer	Recruiting	GBR	0
NCT06560632	Phase I	Olaparib + RP-3467 RP-3467	Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR)	Not yet recruiting	USA	0
NCT06594679	Phase Ib/II	Abemaciclib + Niraparib	A Study of Niraparib in Combination with Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) (NICHOL)	Not yet recruiting	ITA	0
NCT06638931	Phase II	Nivolumab	Agnostic Therapy in Rare Solid Tumors (ANTARES)	Recruiting	BRA	0

ID	DOID:1964
Name	fallopian tube cancer
Definition	A female reproductive organ cancer that is located_in fallopian tube.
Source	DiseaseOntology.org
Alt Ids	DOID:1961
Path	disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer fallopian tube cancer

Disease Detail

Contact

Filtering

Sorting